Health Care · Biological Products, (No Diagnostic Substances) · Nasdaq · CIK 1812364 · FYE Dec 31 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote
Last $18.37Day +0.44%Mkt cap $3.5B1Y +407.5%Off 52W high −11.6%Vol (1Y) 73.8%
Daily closing price, split-adjusted to the current basis; 3y shown of 1,360 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest22.2% of sh out |
| Days to cover13.4d |
| 13F net flow (QoQ)+10.44% |
| Top-10 13F concentration61.4% |
| Next report (est.)2026-08-05 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$10.7M |
| Earnings (TTM)-$272.7M |
| ROE−41.1% |
| Net margin−1800.6% |
| Sales growth 3Y123.2% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD+117.1% |
| 1Y+407.5% |
| 3Y+45.8% |
| 5Y−43.8% |
| Since incept. (ann.)−14.9% |
Total return through 2026-07-29 · series begins 2021-02-22. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)73.8% |
| Ann. volatility (3Y)77.2% |
| Sharpe (1Y)2.58 |
| Sharpe (3Y)0.54 |
| Max drawdown (1Y)−28.2% |
| Max drawdown (3Y)−84.1% |
| Beta (3Y vs SPY)2.15 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| SB INVESTMENT ADVISERS (UK) LTD | 27.9M | $278M | 14.57% | +0.0% |
| Commodore Capital LP | 17.0M | $169M | 8.87% | +0.0% |
| Casdin Capital, LLC | 14.4M | $143M | 7.53% | +10.9% |
| BlackRock, Inc. | 13.0M | $129M | 6.77% | −1.9% |
| PERCEPTIVE ADVISORS LLC | 9.8M | $97M | 5.09% | +412.3% |
| Bellevue Group AG | 7.8M | $78M | 4.07% | −6.6% |
| VANGUARD CAPITAL MANAGEMENT LLC | 7.4M | $74M | 3.86% | new |
| STATE STREET CORP | 6.2M | $62M | 3.25% | −3.0% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-05 | −$0.41 | — | $3.0M | −60.9% |
| 2025-12-31 | 2026-02-26 | — | — | $7.0M | — |
| 2025-09-30 | 2025-11-06 | −$0.43 | — | $0 | — |
| 2025-06-30 | 2025-08-07 | −$0.41 | — | $677,000 | — |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-05 is ESTIMATED from filing cadence (median gap 92d) — not company-confirmed.
